Literature DB >> 2886315

Tissue distribution, disposition, and metabolism of cyclosporine in rats.

O Wagner, E Schreier, F Heitz, G Maurer.   

Abstract

Tissue distribution, disposition, and metabolism of 3H-cyclosporine were studied in rats after single and repeated oral doses of 10 and 30 mg/kg and after an iv dose of 3 mg/kg. The oral doses of 10 and 30 mg/kg were dissolved in polyethylene glycol 200/ethanol or in olive oil/Labrafil/ethanol. Absorption from both formulations was slow and incomplete, with peak 3H blood levels at 3-4 hr. Approximately 30% of the radioactive dose was absorbed, which is consistent with oral bioavailability data for cyclosporine. More than 70% of the radioactivity was excreted in feces and up to 15% in urine. Elimination via the bile accounted for 10 and 60% of the oral and iv doses, respectively. Since unchanged cyclosporine predominated in both blood and tissues at early time points, the half-lives of the distribution phases (t 1/2 alpha) of parent drug and of total radioactivity were similar. In blood, kidney, liver, and lymph nodes, t 1/2 alpha of cyclosporine ranged from 6-10 hr. Elimination of radioactivity from the systemic circulation was multiphasic, with a terminal half-life of 20-30 hr. 3H-Cyclosporine was extensively distributed throughout the body, with highest concentrations in liver, kidney, endocrine glands, and adipose tissue. The concentrations of both total radioactivity and parent drug were greater in tissues than in blood, which is consistent with the high lipid solubility of cyclosporine and some of its metabolites. Skin and adipose tissue were the main storage sites for unchanged cyclosporine. Elimination half-lives were slower for most tissues than for blood and increased with multiple dosing. The amount of unchanged drug was negligible in urine and bile.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886315

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat.

Authors:  Ken-ichi Umehara; Gian Camenisch
Journal:  Pharm Res       Date:  2011-10-20       Impact factor: 4.200

Review 2.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

3.  Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center.

Authors:  Akira Okada; Hidetaka Ushigome; Misaki Kanamori; Aya Morikochi; Hidefumi Kasai; Tadashi Kosaka; Takatoshi Kokuhu; Asako Nishimura; Nobuhito Shibata; Keizo Fukushima; Norio Yoshimura; Nobuyuki Sugioka
Journal:  Eur J Clin Pharmacol       Date:  2017-06-15       Impact factor: 2.953

4.  Species-specific cyclosporine metabolism.

Authors:  R Venkataramanan; C P Wang; K Habucky; R J Ptachcinski; G J Burckart; B Koneru; R Baker; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

5.  Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK model.

Authors:  Cécile Gérard; Nathalie Bleyzac; Pascal Girard; Gilles Freyer; Yves Bertrand; Michel Tod
Journal:  Pharm Res       Date:  2010-09-02       Impact factor: 4.200

6.  Physiologic modeling of cyclosporin kinetics in rat and man.

Authors:  A Bernareggi; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1991-02

7.  Ciclosporin metabolite pattern in blood and urine of liver graft recipients. II. Influence of cholestasis and rejection.

Authors:  U Christians; K Kohlhaw; J Budniak; J S Bleck; R Schottmann; H J Schlitt; V M Almeida; M Deters; K Wonigeit; R Pichlmayr
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  The interaction of the diltiazem with oral and intravenous cyclosporine in rats.

Authors:  Sule Kalkan; Mukaddes Gumustekin; Oguz Aygoren; Yesim Tuncok; Ayse Gelal; Hulya Guven
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

9.  Improvement of cyclosporin A-induced cholestasis by tauroursodeoxycholate in a long-term study in the rat.

Authors:  P E Queneau; P Bertault-Peres; M Guitaoui; E Mesdjian; A Durand; J C Montet
Journal:  Dig Dis Sci       Date:  1994-07       Impact factor: 3.199

Review 10.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.